Research Highlights:

  • Results of a large, international clinical trial on the novel medication finerenone indicate it reduced the rate of death, heart attack, stroke and hospitalization for heart failure among patients with chronic kidney disease and Type 2 diabetes.
  • Finerenone helped patients with chronic conditions improve their heart health, regardless of if they had a history of cardiovascular disease.

Embargoed until 7:10 p.m. CT/8:10 p.m. ET, Monday, Nov. 16, 2020

DALLAS, Nov. 16, 2020 — The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2020. The virtual meeting is Friday, November 13-Tuesday, November 17, 2020, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide. The manuscript of this study is simultaneously published today in Circulation, journal of the American Heart Association.

In the largest trial of its kind to-date, the study, “Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes” (FIDELIO-DKD), found that finerenone reduced the risk of cardiac events for patients regardless of whether they had a history of heart disease or not. Finerenone – a novel, nonsteroidal, selective mineralocorticoid receptor antagonist – reduced both the risk of worsening kidney disease and risk of death related to heart problems.

“We are pleased to see that finerenone could provide a meaningful treatment option for patients who are battling chronic conditions,” said Gerasimos Filippatos, M.D., the study’s lead author and a professor of cardiology at the National and Kapodistrian University of Athens in Greece.

The FIDELIO-DKD study is a phase III, randomized, double-blind, placebo-controlled trial that enrolled nearly 6,000 patients (average age 66; 70.2% male) at more than 900 sites in 48 countries. The goal was to investigate finerenone in patients with chronic kidney disease and Type 2 diabetes since these patients face significant risk of cardiovascular disease and death. Cardiovascular events like heart attacks, heart failure and stroke are some of the leading causes of death in this patient group.

After follow-up of more than 2-1/2 years, researchers found a daily, oral treatment at 10 mg or 20 mg with finerenone reduced by 14% the risk of cardiovascular events for patients who already had a history of heart disease and for those who had no previous history. It also reduced the rate of death, heart attack, stroke and hospitalization for heart failure among patients with chronic kidney disease and Type 2 diabetes.

There are additional phase III trials of finerenone in progress.

Co-authors are Stefan D. Anker, M.D.; Rajiv Agarwal, M.D., M.S.; Bertram Pitt, M.D.; Peter Rossing, M.D.; Luis M. Ruilope, M.D.; Peter Kolkhof, Ph.D.; Patrick Schloemer, Ph.D.; Amer Joseph, M.B.B.S.; Ingo Tornus, Ph.D.; and George L. Bakris, M.D. Author disclosures are in the abstract. The study was funded by Bayer AG.

Presentation: LBS.07 - Randomized Trials – Brain, Kidney, and Heart

Additional Resources:

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on, Facebook, Twitter or by calling 1-800-AHA-USA1.


For Media Inquiries and AHA Expert Perspective:

AHA News Media in Dallas: 214-706-1173;

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and